CUVPOSA

This brand name is authorized in United States. It is also authorized in Canada.

Active ingredients

The drug CUVPOSA contains one active pharmaceutical ingredient (API):

1
UNII V92SO9WP2I - GLYCOPYRROLATE
 

Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways.

 
Read more about Glycopyrronium

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 CUVPOSA Oral solution MPI, US: SPL/PLR FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
A03AB02 Glycopyrronium bromide A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03A DRUGS FOR FUNCTIONAL BOWEL DISORDERS → A03AB Synthetic anticholinergics, quaternary ammonium compounds
Discover more medicines within A03AB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
CA Health Products and Food Branch 02469332
US FDA, National Drug Code 0259-0501

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.